Hunan Warrant Pharmaceutical Technology Development Co. Ltd. has disclosed data on the identification of a novel small-molecule inhibitor of Bruton tyrosine kinase (BTK), HND-01, which was identified by modifying metabolite 20 of dasatinib and is being developed for the potential treatment of cancer.
It is known that Bruton tyrosine kinase (BTK) is an essential enzyme for the FcεRI signaling pathway and is thought to be a target to prevent IgE-mediated allergic reactions. Researchers have hypothesized that the BTK inhibitor acalabrutinib may prevent reactivity to peanuts in patients with peanut allergy.
Therapies for multiple sclerosis (MS) have been effective in relapse prevention but emerging data still show the continued disability progression independent of relapse activity (PIRA), characterized by the presence of ectopic B-cell follicles and active lesions with microglia cells, resulting in a smoldering central nervous system (CNS)-driven inflammation, tissue damage and disease progression.
Innocare Pharma Ltd. said it is open to new collaborations after partner Biogen Inc. decided to terminate a global deal to develop and commercialize BTK inhibitor orelabrutinib, in development for multiple sclerosis and other autoimmune diseases. Notice of the termination, disclosed in Biogen’s fourth-quarter 2022 financial report, was “based on the contract term of ‘terminate for convenience,’” Innocare told BioWorld. “We do not know their internal decision-making process.”
Mantle cell lymphoma (MCL) patients developing resistance to existing BTK inhibitors now have a new treatment option, with the U.S. FDA’s accelerated approval of Jaypirca (pirtobrutinib) from Eli Lilly and Co.’s oncology unit, Loxo@Lilly. It is indicated for use in adults with relapsed or refractory disease who have received at least two lines of systemic therapy, including a BTK inhibitor.
Bionova Pharmaceuticals Ltd. has identified heteroaromatic carboxamide compounds acting as Bruton tyrosine kinase (BTK) and BTK (C481S mutant) inhibitors reported to be useful for the treatment of asthma, cancer, graft-vs.-host disease, inflammatory bowel disease, psoriasis, thrombotic thrombocytopenic purpura, rheumatoid arthritis and autoimmune thyroiditis, among others.
Medshine Discovery Inc. has identified imidazopyridine compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of autoimmune diseases.
Xi'an Xintong Medicine Research Co. Ltd. has synthesized 1,3-benzodioxolane-containing compounds acting as dual Bruton tyrosine kinase (BTK) and tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of rheumatoid arthritis and B-cell lymphoma.
Innocare Pharma Ltd. raised ¥2.92 billion (US$412 million) in a second listing on the Shanghai STAR Market. Its shares opened at ¥10.86 apiece, sliding 15.4% to close at ¥9.33 on the first trading day, Sept. 21. The company will use the proceeds to support cancer and autoimmune drug R&D, improve its drug development platform, build its sales network, and upgrade its information technology, said Chief Commercial Officer Jin Xiaodong.
Innocare Pharma Ltd. raised ¥2.92 billion (US$412 million) in a second listing on the Shanghai STAR Market. Its shares opened at ¥10.86 apiece, sliding 15.4% to close at ¥9.33 on the first trading day, Sept. 21. The company will use the proceeds to support cancer and autoimmune drug R&D, improve its drug development platform, build its sales network, and upgrade its information technology, said Chief Commercial Officer Jin Xiaodong.
